NCT01523067已完成1 期
Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Adult Subjects With Stage 1 or Stage 2 Essential Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 68
- 试验地点
- 5
- 主要终点
- Safety/Tolerability
研究概览
简要总结
The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of Vasomera (PB1046) administered subcutaneously in adult subjects with Stage 1 or Stage 2 essential hypertension.
The secondary objectives of the study are to characterize the pharmacokinetic profile of single ascending doses of Vasomera and the relationship between serum concentrations of Vasomera and change in systolic and diastolic blood pressure as measured by:
- Mean change from baseline in 24-hour systolic and diastolic blood pressure measured by ambulatory blood pressure monitoring (ABPM) as compared to placebo.
- Identification of the minimum and maximum decrease in systolic and diastolic blood pressure as measured by ABPM.
- Mean change from baseline in cuff systolic and diastolic blood pressure as compared to placebo.
- Effect of Vasomera on pulse pressure and heart rate.
An additional secondary objective of this study will be to characterize the immunogenicity profile of Vasomera following a single subcutaneous dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to sign a written informed consent and follow all study related procedures.
- •Males or females age 18 - 70 years of age inclusive.
- •Male and female subjects of childbearing potential must be willing and able to practice effective contraception during the study, and be willing and able to continue contraception for 1 month after their last dose of study drug.
- •Diagnosis of essential hypertension and: Has a systolic blood pressure between 140-169 mmHg (between 130-169 mmHg if subject has type 2 diabetes mellitus (T2DM)) or diastolic blood pressure 90-109 mmHg (between 85 - 109 if subject has T2DM) who is not currently on antihypertensive therapy.
- •or- Has been taking up to two antihypertensive agents to control blood pressure and who in the opinion of the investigator could be safely withdrawn from antihypertensive therapy.
- •BMI ≥ 20 but ≤ 40 kg/m2
- •The difference (highest to lowest mean values) in mean seated systolic blood pressure (triplicate measurements at 1-2 minute interval) measured on three separate occasions between Day -4 and Day 0 (pre-dose) is within 14 mmHg and diastolic is within 8 mmHg.
- •Judged by the Investigator to be in generally stable health (except for hypertension) defined as absence of clinically significant laboratory abnormalities, vital signs, ECG findings or clinically significant underlying disease that would put the subject at risk for participation in the study, or would interfere with interpretation of the study results (i.e., secondary hypertension).
- •Receiving stable doses of protocol permitted concomitant medications for 1 month prior to study drug administration with no anticipated dose adjustments during the study period.
排除标准
- •Screening (triplicate sitting reading 1-2 minutes apart) BP > 169 mmHg (systolic) or > 109 mmHg (diastolic).
- •Systolic blood pressure < 130 mmHg or > 169 mmHg and diastolic blood pressure < 85 mmHg or > 109 mmHg at randomization (Day -1) or prior to the first dose of study drug (Day 0)
- •Unstable/underlying cardiovascular disease defined as in protocol.
- •Uncontrolled type 2 diabetes mellitus defined as hemoglobin A1c > 9.0%
- •Clinically significant renal and/or hepatic dysfunction at Screening or at baseline (Day -4) as defined in protocol.
- •Use of non-steroidal anti-inflammatory drugs (excluding prophylactic use of low dose aspirin such as 81 - 162 mg) within 2 weeks prior to administration of study drug or anticipated use during the study period.
- •Pregnant or lactating females.
- •Known latex allergy (Ambulatory Blood Pressure Monitor [ABPM] unit contains latex in bladder and tubing).
- •Known history of or active drug or alcohol abuse within the 12 months prior to Screening and/or positive drug screen or detection of alcohol at Screening or at baseline (Day -4).
- •Positive for Human Immunodeficiency Virus (HIV) antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies.
- •Participation in any other study and have received any other investigational drug or device within 30 days prior to the Screening visit or are taking part in a non-drug study which in the opinion of the Investigator would interfere with the outcome of the study.
- •Major surgery, donated or lost > or = 1 unit of blood (approximately 500 mL) within 1 month prior to randomization (Day -1) or display evidence of volume depletion (i.e., postural hypotension) not otherwise explained by the subject's antihypertensive medication regimen.
- •Other medical or psychiatric condition which in the opinion of the Investigator would place the subject at increased risk, would preclude obtaining voluntary consent, or would interfere with the interpretation of the results of the study.
研究组 & 干预措施
Vasomera (PB1046)
Active Comparator
干预措施: Vasomera (PB1046) (Drug)
0.9% Sodium Chloride
Placebo Comparator
干预措施: 0.9% Sodium Chloride (Drug)
结局指标
主要结局
Safety/Tolerability
时间窗: Day -45 to Day 28
* Incidence and severity of adverse events (AEs) and their relationship to Vasomera (including AEs of interest, gastrointestinal effects, injection site reaction and hypotension) * Changes in vital signs, ECGs, and safety laboratory parameters from baseline * Discontinuations from the study due to AEs
次要结局
- Pharmacokinetics(Pre-dose, 1, 2, 3, 6, 8 and 12 hours post-dose, 24, 30 and 36 hours, Days 2, 3, 6, 7, 14, 21 and 28)
- Pharmacodynamics(ABPM (Day 0 and Day 6), Telemetry (Day -1, 0, 1 and Day 2 and 3 as needed), Daily home BP monitoring and Vital Signs (up to 3x times/day) during each visit (Day -35, -14, -7, -4, -1, 0, 1, 2, 3, 6, 7, 14, 21 and 28))
- Immunogenicity(Pre-dose, Day 14 and Day 28)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy VolunteersHealthy VolunteerNCT03645746Regeneron Pharmaceuticals56
已完成
1 期
A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy ParticipantsHealthyNCT05481333Regeneron Pharmaceuticals64
已完成
1 期
A Study of the Safety and Tolerability of GWP42006 in Healthy SubjectsEpilepsyNCT01918735Jazz Pharmaceuticals66
终止
1 期
Single Ascending Doses of BIIB063 in Healthy VolunteersHealthyNCT02555085Biogen29
已完成
1 期
A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the BodyHealthy SubjectsNCT03173625Viatris Innovation GmbH72